Journal of Thrombosis and Thrombolysis最新文献

{"title":"Robustness and fragility of evidence supporting systemic thrombolysis in acute pulmonary embolism.","authors":"Marco Zuin, Walter Ageno, Maria Cristina Vedovati, Roman Chopard, Samuel Z Goldhaber, Paolo Simioni","doi":"10.1007/s11239-026-03344-x","DOIUrl":"10.1007/s11239-026-03344-x","url":null,"abstract":"<p><p>Systemic thrombolysis is recommended for high-risk PE and select intermediate-risk patients. We assessed the robustness of RCT evidence comparing systemic thrombolytic therapy with standard anticoagulation. We systematically reviewed RCTs of intravenously administered alteplase or tenecteplase versus heparin. The primary endpoint was all-cause mortality; secondary endpoints included recurrent PE, clinical deterioration in intermediate-risk patients, and major bleeding. Fragility index (FI) or reverse FI (RFI) and fragility quotient (FQ) or reverse FQ (RFQ) were calculated to assess outcome stability. Absolute and relative risk reductions, number needed to treat (NNT), and number needed to harm (NNH) were also derived. Nine RCTs enrolling 1,682 patients met inclusion criteria. Overall, systemic thrombolysis was associated with a nonsignificant reduction in mortality (1.7% vs. 3.8%; RR 0.73; 95% CI 0.39-1.38; p = 0.33) with moderate robustness (RFI = 8; RFQ = 0.004; NNT 91; RRR 27%; ARR 2.1%). Mortality was highly fragile in high-risk PE (RFI = 0) and fragile in intermediate-risk patients (RFI = 4). Systemic thrombolysis moderately reduced recurrent PE (RR 0.42; 95% CI 0.18-0.97; FI = 5; RFQ = 0.002) and prevented clinical deterioration in intermediate-risk patients (RR 0.31; 95% CI 0.15-0.65; FI = 8; RFQ = 0.006; NNT 29; RRR 71%; ARR 3.5%). Major bleeding was robustly increased (FI = 30; RFQ = 0.001; NNH 17), mainly driven by tenecteplase (FI = 9; RFQ = 0.007; NNH 11), whereas alteplase showed no significant increase (RFI = 3). Mortality benefit of systemic thrombolysis is fragile, while major bleeding risk is robust, underscoring the limitations of current guidelines and the need for adequately powered RCTs to inform individualized treatment in high- and intermediate-risk PE.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1996-2006"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative models.","authors":"Richard C Becker","doi":"10.1007/s11239-026-03262-y","DOIUrl":"10.1007/s11239-026-03262-y","url":null,"abstract":"<p><p>Cancer therapeutics account for a significant proportion of new drug development, reflecting advances in diagnosis, treatment, and disease control. However, with this trend comes a responsibility to ensure patient safety both in the near term and over the long term. Among these considerations, cardiovascular safety is a priority. Downsizing and resource constraints within regulatory agencies, particularly the United States Food and Drug Administration (FDA) threaten safety oversight capacity, increasing the need for automation, structured data standards, common data elements and shared analytics. Public health policy, public-private partnerships, big data capabilities, and the FDA Oncology Center of Excellence (OCE) provide avenues to strengthen Cardio-Oncology safety through cross-center coordination, technology advances, guidance development, and methodological innovation. In this third offering of a 3-part series, the objective is to outline public-private partnerships and collaborative oversight models, linking sponsors, regulators, health systems, payers, and patient groups to operationalize continuous surveillance, standardized cardiac endpoints, and transparent data sharing. Building on existing scientific and regulatory foundations, there is a pressing need to leverage contemporary technologies and creative, interdisciplinary thinking to advance predictive models, monitoring strategies, and mitigation frameworks. A strategic forecasting and preparedness framework is proposed that includes embedding fit-for-purpose cardiac safety endpoints early in development; interoperable, real-time safety data pipelines across pre- and post-marketing phases; deploying artificial intelligence (AI)-enabled signal detection with human-in-the-loop adjudication; using real world evidence (RWE) to confirm clinical benefit-risk under accelerated approvals; and pre-specifying label-update triggers tied to cardiac signal thresholds. Together, these policy and technology innovations can modernize cardiotoxicity detection, protect patients, and sustain benefits in oncology care.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1857-1867"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-dependent efficacy and safety of endovascular treatment in anterior circulation stroke: A systematic review and meta-analysis.","authors":"Rafaella Valli Santanna, Valdecir B S Júnior, Thiago B Schuster, Fernando B Bezerra, Giovanna V R Marques, Maria E B V Rosa, Vithor E B da Silva","doi":"10.1007/s11239-026-03328-x","DOIUrl":"10.1007/s11239-026-03328-x","url":null,"abstract":"<p><p>Acute ischemic stroke of the anterior circulation is a leading cause of mortality and disability. Although endovascular treatment combined with medical therapy (EVMT) has demonstrated substantial efficacy, its risk-benefit profile across different treatment windows remains uncertain. This meta-analysis aimed to evaluate the impact of time from symptom onset on the efficacy and safety of EVMT compared with best medical therapy (BMT) alone. PubMed, Embase, and the Cochrane Library were searched from inception to June 30, 2025. Randomized clinical trials enrolling adults with anterior circulation acute ischemic stroke assigned to EVMT versus BMT were included. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using random-effects models in RevMan version 5.4. The I² statistic was used to measure heterogeneity. Nineteen trials comprising 5,209 patients (2,517 EVMT; 2,692 BMT) were included. EVMT was associated with a reduction in 90-day mortality compared with BMT (OR 0.79; 95% CI 0.67-0.93; P = 0.005), with the strongest effect within ≤ 12 h (OR 0.63; 95% CI 0.46-0.86; P = 0.003). Functional outcomes consistently favored EVMT across all windows (OR 2.44; 95% CI 1.97-3.01; P < 0.0001). EVMT was associated with an overall increased risk of symptomatic intracranial hemorrhage (OR 1.68; 95% CI 1.26-2.23; P = 0.0004), including in the ≤ 12 h, ≤ 24 h, and 6-24 h subgroups, but not within ≤6 h. Treatment effects were significant across time windows, however, with no significant interaction detected. EVMT improves functional outcomes across all evaluated time windows, with a favorable safety profile within 6 h from symptom onset and an |increased hemorrhagic risk with delayed treatment, without evidence of significant effect modification by time.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1886-1897"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protein-protein interaction disruption as a next-generation antithrombotic strategy.","authors":"Emadeldin M Kamel, Sally Mostafa Khadrawy, Mohamed A M Ali, Noha A Ahmed, Nour Y S Yassin, Saleh Alkhedhairi, Faris F Aba Alkhayl, Al Mokhtar Lamsabhi","doi":"10.1007/s11239-026-03308-1","DOIUrl":"10.1007/s11239-026-03308-1","url":null,"abstract":"<p><p>Thrombosis is built, not merely catalyzed. Across arterial and venous disease, thrombus formation depends on a succession of protein-protein interactions (PPIs) that coordinate platelet capture and activation, thromboinflammatory amplification, and assembly of membrane-bound coagulation complexes. Although active-site inhibitors and receptor antagonists have transformed antithrombotic therapy, clinical benefit is often constrained by bleeding because many targets are indispensable for everyday hemostasis when inhibited systemically. This review advances a \"thrombus assembly\" framework that reframes drug discovery around disrupting interfaces that organize pathologic clot growth in a context-dependent manner shaped by shear, surfaces, local cofactors, and transient complex formation. We highlight translational proof that interface blockade works in humans, focusing on VWF A1-GPIbα inhibition and GPVI-directed strategies as exemplars of lesion- and shear-dependent antiplatelet therapy. We then survey platelet adhesion and activation PPIs (VWF-GPIb, collagen-GPVI, and αIIbβ3-ligand interactions), thromboinflammatory interfaces (including P-selectin-PSGL-1 and CLEC-2-podoplanin), and opportunities to target coagulation complex assembly and thrombin exosites without directly inhibiting catalytic active sites. A modality-focused section links interface class to therapeutic format-antibodies/nanobodies, aptamers with antidotes, peptides and macrocycles, and small-molecule PPI inhibitors-and summarizes trade-offs in reversibility, half-life, manufacturability, and immunogenicity. Finally, we discuss assays that preserve interface biology (whole-blood flow systems, microfluidics, thrombin generation, and clot mechanics) and propose clinical positioning and trial endpoints for context-gated mechanisms. By targeting the contacts that assemble and stabilize thrombi, PPI disruption offers a pragmatic route toward more selective, potentially bleeding-sparing antithrombotic therapy and a roadmap for next-generation pipeline development.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1680-1710"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of different doses of intravenous thrombolytics in acute ischemic stroke: a GRADE-assessed network meta-analysis of randomized controlled trials.","authors":"Haneen Sabet, Moaz Elsayed Abouelmagd, Abdelrahman Shata, Mohamed El-Moslemani, Diana Kadi, Dina Essam Abo-Elnour, Abdallah Abbas, Ramanathan Kadirvel, Sherief Ghozy","doi":"10.1007/s11239-026-03325-0","DOIUrl":"10.1007/s11239-026-03325-0","url":null,"abstract":"<p><p>To compare the efficacy and safety of different doses of intravenous thrombolytic agents in patients with acute ischemic stroke (AIS) and guide optimal dose selection. We searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL until March 2025 to identify randomized controlled trials (RCTs) evaluating alteplase (tPA), tenecteplase (TNK), reteplase, and recombinant human prourokinase (rhPro-UK) at any dose in patients with AIS. Analysis was performed using R software, and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled. Primary outcomes included symptomatic intracranial hemorrhage (sICH), 90-day mortality, excellent functional outcome (defined as modified Rankin Scale [mRS] score 0-1), and functional independence (defined as mRS 0-2). We included 21 RCTs (16,643 patients). Compared to tPA (0.9 mg/kg), tPA (0.6 mg/kg) was associated with a significantly lower risk of sICH (RR = 0.48, 95% CI: 0.27-0.86), while TNK (0.4 mg/kg) showed a higher risk (RR = 1.88, 95% CI: 1.06-3.35). No significant differences were observed in 90-day mortality, functional independence, or serious adverse events across interventions. Reteplase (18 + 18 mg) (RR = 1.13, 95% CI: 1.05-1.21) and TNK (0.25 mg/kg) (RR = 1.05, 95% CI: 1.01-1.10) significantly improved 90-day excellent functional recovery compared to tPA (0.9 mg/kg). TNK (0.32 mg/kg) showed the lowest risk probability for any ICH and parenchymal hemorrhage. Some safety outcomes showed dose-dependent effects: lower-dose tPA and intermediate-dose TNK reduced ICH risk compared to higher doses, while mortality and functional independence remained comparable across doses.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1910-1929"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory challenges and current policy for cardiotoxicity detection in oncology drug development.","authors":"Richard C Becker","doi":"10.1007/s11239-026-03337-w","DOIUrl":"10.1007/s11239-026-03337-w","url":null,"abstract":"<p><p>The rapid evolution of oncology therapeutics, particularly targeted agents, antibody-drug conjugates, and immunotherapies has outpaced existing regulatory frameworks for detecting and managing cardiotoxicity. Current gaps include inconsistent cardiac safety requirements across development phases, limited incorporation of Cardio-Oncology endpoints within expedited approval pathways, and inadequate harmonization of post-marketing signal detection. These deficiencies underscore the need for a modernized, system-level approach that integrates regulatory science with real-world cardiovascular risk. This review examines approval processes of the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including expedited pathways such as Breakthrough Therapy, Accelerated Approval, PRIority Medicines (PRIME), and upstream activities in pivotal trials. It highlights their strengths in pre-approval drug dose safety and reducing time-to-therapy while critically evaluating limitations in pre-approval cardiac phenotyping, reliance on surrogate endpoints for cardiotoxicity assessment, and constrained post-market surveillance infrastructures that delay informed, patient-centered understanding of safety and efficacy following drug approval.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1842-1856"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148055246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Verification and optimization of the VTE risk stratification system for multiple myeloma.","authors":"Yuexiao Liu, Qian Li, Huixia Guo, Yue Wu, Yijuan Chen, Yang Liu, Xuelin Dou, Nan Peng, Xiaodong Mo, Jin Lu, Liru Wang","doi":"10.1007/s11239-026-03339-8","DOIUrl":"10.1007/s11239-026-03339-8","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) is a common complication in multiple myeloma (MM), particularly within the first six months of treatment initiation and disease relapse. This study optimized the MM-VTE risk stratification system to enable early and accurate identification of VTE risk. We retrospectively analyzed 433 newly diagnosed MM (NDMM) patients from Fu Xing Hospital, Capital Medical University, who were divided into derivation (n = 332) and validation (n = 101) cohorts. Independent risk factors were identified using univariate and multivariate analyses. The optimized MM-VTE risk stratification system was constructed by integrating the identified independent risk factors and thromboprophylaxis status. Model performance was assessed using the area under the curve (AUC). Internal validation was performed with bootstrap resampling, and external validation was conducted using the validation cohort. In the derivation cohort, the 6-month VTE incidence was 8.43% (28/332). Independent risk factors included female sex, bed rest at diagnosis, and platelet count above the upper limit of normal. The optimized MM-VTE risk stratification system was developed by integrating these factors and thromboprophylaxis. The AUC for the IMWG score was 0.605, and the AUCs for the MM-VTE risk stratification system before and after optimization were 0.660 and 0.742, respectively. In the validation cohort, the AUCs of the MM-VTE risk stratification system before and after optimization were 0.659 and 0.730, respectively.The optimized MM-VTE risk stratification system demonstrated improved discriminatory performance in our cohort, offering a potentially more reliable and clinically accessible tool for guiding thromboprophylaxis in Chinese patients.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1868-1876"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long non-coding RNA NPPA-AS1 acts as a potential novel biomarker and promotes atrial fibrillation progression via the miR-302e/TGFBR2 axis.","authors":"Sheng Li, Nina Chen, Qingli Wang, Bo Li, Youlin Fu","doi":"10.1007/s11239-026-03327-y","DOIUrl":"10.1007/s11239-026-03327-y","url":null,"abstract":"<p><p>Atrial fibrillation (AF) has complex etiologies. This study aimed to investigate the clinical significance of long non-coding RNA (lncRNA) NPPA-AS1 in AF and the pro-AF mechanism of the NPPA-AS1/miR-302e/transforming growth factor beta receptor 2 (TGFBR2) axis. This study included 120 patients with AF and 120 healthy controls. An in vitro AF model was established by stimulating rat primary cardiac fibroblasts (CFs) with angiotensin II (AngII). RT-qPCR, Cell Counting Kit-8 (CCK-8) assay, flow cytometry, and enzyme-linked immunosorbent assay (ELISA) were utilized to assess gene expression, cellular function, and protein concentration, respectively. Molecular target regulation relationships were validated using RNA immunoprecipitation (RIP) and dual luciferase assays. Target genes predicted by multiple databases were selected for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to investigate the biological functions and related signaling pathways of the NPPA-AS1/miR-302e axis. NPPA-AS1 was highly expressed in AF patients, serving as an independent risk factor for AF onset while demonstrating excellent diagnostic efficacy for AF. Its expression may be closely associated with cardiac structural remodeling, myocardial injury, and inflammatory responses in AF patients. Mechanistically, NPPA-AS1 was found to act as a molecular sponge to negatively regulate miR-302e, which directly suppressed TGFBR2 expression, forming the NPPA-AS1/miR-302e/TGFBR2 regulatory axis. In vitro, this regulatory axis was associated with Ang II-induced cellular proliferation, apoptosis imbalance, expression of fibrotic molecules, and inflammatory factor secretion (tumor necrosis factor alpha [TNF-α], interleukin 6 [IL-6]), suggesting a potential role in AF-related pathological processes. Specifically, interference with NPPA-AS1 reversed these pathological effects, while inhibition of miR-302e counteracted this reversal. Further interference with TGFBR2 could re-block the pathological process. In vitro findings suggest that NPPA-AS1 may amplify AngⅡ-induced atrial fibrosis and inflammation by releasing TGFBR2 inhibition through \"sponge-like\" adsorption of miR-302e, indicating a potential contributory role in AF pathogenesis.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1777-1791"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The COOL-AF 3-year prediction models for death, ischemic stroke, and major bleeding: a report from the COOL-AF registry.","authors":"Satchana Pumprueg, Gregory Y H Lip, Chulaluk Komoltri, Ahthit Yindeengam, Rungroj Krittayaphong","doi":"10.1007/s11239-026-03333-0","DOIUrl":"10.1007/s11239-026-03333-0","url":null,"abstract":"<p><p>Patients with atrial fibrillation (AF) are at increased risk of death, ischemic stroke/systemic embolism (SSE), and major bleeding. Most existing risk models focus on short-term outcomes and are derived mainly from Western populations. We aimed to develop and validate 3-year prediction models for these outcomes in an Asian AF cohort and to compare their performance with established risk scores. We analyzed the 3-year data from the prospective, nationwide COOL-AF registry, enrolling patients with non-valvular AF from 27 hospitals in Thailand. Multivariable Cox proportional hazards models were used to derive prediction models for death, SSE, and major bleeding. Model performance was assessed using discrimination (C-statistics), calibration, and reclassification metrics, and compared with GARFIELD, CHA₂DS₂-VASc, and HAS-BLED models. Among 3,405 patients, 380 deaths, 134 SSE events, and 199 major bleeding events occurred over a median follow-up of 35.9 months. The 3-year COOL-AF models showed good discrimination, with C-statistics of 0.728 (0.712-0.743) for death, 0.703 (0.687-0.718) for SSE, and 0.700 (0.685-0.716) for major bleeding, and demonstrated good calibration. Compared with existing scores, the COOL-AF models performed better than CHA₂DS₂-VASc for death and better than HAS-BLED for major bleeding, while showing comparable or superior performance to the GARFIELD models, particularly for bleeding risk. Reclassification indices further supported the incremental value of the COOL-AF models. In conclusion, the 3-year COOL-AF prediction models provide an acceptable levels of prediction, well-calibrated estimates of death, SSE, and major bleeding in Asian patients with AF and outperform commonly used clinical risk scores, supporting their use for long-term risk stratification and clinical decision-making.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1749-1759"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombosis: focus on molecular mechanisms, biomarkers and cardio-oncology.","authors":"Diana A Gorog","doi":"10.1007/s11239-026-03403-3","DOIUrl":"10.1007/s11239-026-03403-3","url":null,"abstract":"","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":"1677-1679"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}